Optimisation or Restriction? Unpacking the Logic Behind NICE Decisions.

Authors

Nadine Henderson, Brittany Darrow, Phill O'Neill, Martina Garau

Published in

PharmacoEconomics. Jul 13, 2026. Epub Jul 13, 2026.

Abstract

The National Institute for Health and Care Excellence (NICE) regularly issues optimised technology appraisal (TA) recommendations, whereby medicines are recommended for a subset of their licensed population. These decisions play a growing role in shaping patient access, yet the underlying drivers and implications of optimisation remain poorly understood.
We conducted a mixed‑methods analysis of all optimised NICE TAs published in 2023 and 2024. Fifty‑six appraisals met our inclusion criteria for qualitative assessment of committee documentation, while 30 provided sufficient data to estimate the degree of patient access using the established M‑score method. Three case studies were developed to illustrate how optimisation rationales translate into real‑world implications for patients.
Of 131 positive decisions in 2023-2024, 50% were optimised. Qualitative thematic analysis identified four interacting drivers of optimisation: (1) match to clinical trial data; (2) match to NHS clinical practice; (3) match to previous NICE guidance; and (4) subgroup only cost effective. Quantitatively, the mean M‑score across optimised decisions was 31%, indicating that, on average, only one‑third of the licensed patient population receives access. Most optimised decisions (77%) granted access to fewer than half of eligible patients. The case studies illustrate how optimisation decisions translate into meaningful consequences for patients, often limiting access to effective treatments and determining the point at which they can receive care.
Optimised decisions constitute a substantial proportion of NICE's positive recommendations and often result in significant restrictions relative to marketing authorisations. Understanding the multifactorial drivers of optimisation is essential for interpreting access and equity implications for patients.

PMID:
42440217
Bibliographic data and abstract were imported from PubMed on 13 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.